Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


16.05.2022

1 AJR Am J Roentgenol
2 Aliment Pharmacol Ther
1 BMC Gastroenterol
5 Clin Gastroenterol Hepatol
6 Gut
10 Inflamm Bowel Dis
2 J Crohns Colitis
1 Z Gastroenterol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    AJR Am J Roentgenol

  1. DILLMAN JR, Tkach JA, Imbus R, Towbin AJ, et al
    MRI-Based Characterization of Intestinal Motility in Children and Young Adults With Newly Diagnosed Ileal Crohn Disease Treated by Biologic Therapy: A Controlled Prospective Study.
    AJR Am J Roentgenol. 2022 May 11. doi: 10.2214/AJR.22.27792.
    PubMed         Abstract available


    Aliment Pharmacol Ther

  2. YUAN WQ, Li F, Yang LC, Yang ZL, et al
    Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID-19 pandemic.
    Aliment Pharmacol Ther. 2022;55:1464-1465.
    PubMed        

  3. WANG CY, Lai CC
    Letter: the effect of anti-COVID-19 treatment on the outcome of patients with inflammatory bowel disease.
    Aliment Pharmacol Ther. 2022;55:1462-1463.
    PubMed        


    BMC Gastroenterol

  4. HIBIYA S, Ohtsuka K, Takenaka K, Kawamoto A, et al
    Mucosal healing of small intestinal stricture is associated with improved prognosis post-dilation in Crohn's disease.
    BMC Gastroenterol. 2022;22:218.
    PubMed         Abstract available


    Clin Gastroenterol Hepatol

  5. FINK M, Simons M, Tomasino K, Pandit A, et al
    When Is Patient Behavior Indicative of Avoidant Restrictive Food Intake Disorder (ARFID) Vs Reasonable Response to Digestive Disease?
    Clin Gastroenterol Hepatol. 2022;20:1241-1250.
    PubMed         Abstract available

  6. DE GREGORIO M, Lee T, Krishnaprasad K, Amos G, et al
    Higher Anti-tumor Necrosis Factor-alpha Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas.
    Clin Gastroenterol Hepatol. 2022;20:1306-1314.
    PubMed         Abstract available

  7. LIU Q, Zhang X, Ko HM, Stocker D, et al
    Constrictive and Hypertrophic Strictures in Ileal Crohn's Disease.
    Clin Gastroenterol Hepatol. 2022;20:e1292-e1304.
    PubMed         Abstract available

  8. KOCHAR B, Pate V, Kappelman MD, Long MD, et al
    Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults.
    Clin Gastroenterol Hepatol. 2022;20:1299-1305.
    PubMed         Abstract available

  9. RIVIERE P, Bislenghi G, Vermeire S, Domenech E, et al
    Postoperative Crohn's Disease Recurrence: Time to Adapt Endoscopic Recurrence Scores to the Leading Surgical Techniques.
    Clin Gastroenterol Hepatol. 2022;20:1201-1204.
    PubMed        


    Gut

  10. RAINE T, Pavey H, Qian W, Moran GW, et al
    Establishment of a validated central reading system for ileocolonoscopy in an academic setting.
    Gut. 2022;71:661-664.
    PubMed        

  11. STIDHAM RW, Vickers A, Singh K, Waljee AK, et al
    From clinical trials to clinical practice: how should we design and evaluate prediction models in the care of IBD?
    Gut. 2022;71:1046-1047.
    PubMed        

  12. KAPLAN GG, Ma C, Charlton C, Kanji JN, et al
    Antibody response to SARS-CoV-2 among individuals with IBD diminishes over time: a serosurveillance cohort study.
    Gut. 2022;71:1229-1231.
    PubMed        

  13. CURTIUS K, Kabir M, Al Bakir I, Choi CHR, et al
    Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool.
    Gut. 2021 May 14. pii: gutjnl-2020-323546. doi: 10.1136/gutjnl-2020-323546.
    PubMed         Abstract available

  14. JIMENEZ-VARGAS NN, Yu Y, Jensen DD, Bok DD, et al
    Agonist that activates the micro-opioid receptor in acidified microenvironments inhibits colitis pain without side effects.
    Gut. 2022;71:695-704.
    PubMed         Abstract available

  15. NARULA N, Wong ECL, Colombel JF, Sandborn WJ, et al
    Predicting endoscopic remission in Crohn's disease by the modified multiplier SES-CD (MM-SES-CD).
    Gut. 2022;71:1078-1087.
    PubMed         Abstract available


    Inflamm Bowel Dis

  16. ZHAO QF, Wang S
    Crohn's Disease Complicated by an Ileo-urachal Fistula.
    Inflamm Bowel Dis. 2022;28:e62-e63.
    PubMed        

  17. HUANG JS, Definis M, Cruz R, Parker J, et al
    Patient Portal Usage: An Objective Target for Transition Interventions Among Youth with IBD?
    Inflamm Bowel Dis. 2022;28:808-810.
    PubMed        

  18. ROBLIN X, Genin C, Nancey S, Williet N, et al
    Swapping Versus Dose Optimization in Patients Losing Response to Adalimumab With Adequate Drug Levels.
    Inflamm Bowel Dis. 2022;28:720-727.
    PubMed         Abstract available

  19. GU P, Chhabra A, Chittajallu P, Chang C, et al
    Visceral Adipose Tissue Volumetrics Inform Odds of Treatment Response and Risk of Subsequent Surgery in IBD Patients Starting Antitumor Necrosis Factor Therapy.
    Inflamm Bowel Dis. 2022;28:657-666.
    PubMed         Abstract available

  20. BRENNER EJ, Long MD, Mann CM, Lin L, et al
    Anxiety and Depressive Symptoms Are Not Associated With Future Pediatric Crohn's Disease Activity.
    Inflamm Bowel Dis. 2022;28:728-733.
    PubMed         Abstract available

  21. DE CRUZ P, Hamilton AL, Burrell KJ, Gorelik A, et al
    Endoscopic Prediction of Crohn's Disease Postoperative Recurrence.
    Inflamm Bowel Dis. 2022;28:680-688.
    PubMed         Abstract available

  22. GOLUSDA L, Kuhl AA, Siegmund B, Paclik D, et al
    Reducing Pain in Experimental Models of Intestinal Inflammation Affects the Immune Response.
    Inflamm Bowel Dis. 2022;28:801-807.
    PubMed         Abstract available

  23. NIGAM GB, Patel RN, Lakhtakia S, Desai D, et al
    A Survey of Endoscopists' Views on Dysplasia Surveillance and Chromoendoscopy in IBD from India.
    Inflamm Bowel Dis. 2022;28:e64-e65.
    PubMed        

  24. ETWEBI Z, Goldsmith JR, Bou-Dargham M, Tian Y, et al
    TIPE2 Promotes Tumor Initiation But Inhibits Tumor Progression in Murine Colitis-Associated Colon Cancer.
    Inflamm Bowel Dis. 2022;28:764-774.
    PubMed         Abstract available

  25. PEREZ K, Ngollo M, Rabinowitz K, Hammoudi N, et al
    Meta-Analysis of IBD Gut Samples Gene Expression Identifies Specific Markers of Ileal and Colonic Diseases.
    Inflamm Bowel Dis. 2022;28:775-782.
    PubMed         Abstract available


    J Crohns Colitis

  26. ALSOUD D, De Hertogh G, Compernolle G, Tops S, et al
    Real-world endoscopic and histologic outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis.
    J Crohns Colitis. 2022 May 9. pii: 6582859. doi: 10.1093.
    PubMed         Abstract available

  27. STODTMANN S, Chen MJ, Siovitz L, Bereswill M, et al
    Bridging Fixed Dose to Body Weight-Based Regimen of Adalimumab in Pediatric Ulcerative Colitis Using a Pharmacometric Modeling Approach: Case Study with the Phase 3 ENVISION I Trial.
    J Crohns Colitis. 2022 May 8. pii: 6582407. doi: 10.1093.
    PubMed         Abstract available


    Z Gastroenterol

  28. SCHOLZ KAM, Thomann AK, Teich N, Baumann H, et al
    Validation of the German Inflammatory Bowel Disease Fatigue (IBD-F) Questionnaire.
    Z Gastroenterol. 2022 May 9. doi: 10.1055/a-1797-2688.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: